Search clinical trials for: B-cell Maturation Antigen

Total 4923 results

Pfizer

Recruiting

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Multiple Myeloma

Japan, United States, Canada
Fundación Pública Andaluza para la gestión de la...

Not yet recruiting

Trial of an Investigational Drug After Rejecting the Relapse of an Allogeneic Transplant (CARTemis-1)

Multiple Myeloma | Allogeneic Stem Cell Transplantation

Spain
Regeneron Pharmaceuticals

Recruiting

A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma

Smoldering Multiple Myeloma (SMM)

Spain
TeneoOne Inc.

Recruiting

A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Israel, United States, Canada, Spain, France, Denmark, United Kingdom
Pfizer

Recruiting

A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135), Daratumumab, and Lenalidomide Compared With Daratumumab, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant (MagnetisMM-6)

Multiple Myeloma

Japan, Taiwan, Canada, Spain, Australia, Italy, Czechia, Korea, Republic of, France, Greece, Israel, Poland, Germany
Cellular Biomedicine Group Ltd.

Recruiting

A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

China
Pfizer

Recruiting

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant (MagnetisMM-7)

Multiple Myeloma

Japan, Belgium, United States, Netherlands, Australia, Austria, Taiwan, China, Spain, Canada, Israel, Germany, Italy, Czechia, Korea, Republic of, Norway, Finland, France, Sweden, Brazil, Greece, Turkey, United Kingdom, Hungary, Poland, I...
Regeneron Pharmaceuticals

Recruiting

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

Multiple Myeloma

United States, Spain, France, Greece
Pfizer

Recruiting

MagnetisMM-5: Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma (MAGNETISMM-5)

Multiple Myeloma

China, Korea, Republic of, Taiwan, United States, Australia, Japan, Spain, Czechia, United Kingdom, Canada, Germany, New Zealand, Italy, France, Sweden, Poland, Netherlands, Austria, Mexico, Finland, Argentina, Belgium, Brazil, Greece, ... and more
Tongji Hospital
Nanjing IASO Biotechnology Co., Ltd.

Recruiting

Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System (CARTinNS)

Multiple Sclerosis | Autoimmune Diseases of the Nervous System | Autoimmune Diseases | Myasthenia Gravis | Neuromyelitis Optica Spectrum Disorder | Autoimmune Encephalitis | Idiopathic Inflammatory Myopathies | Chronic Inflammatory Demyelinating Polyradiculoneuropathy | Myelin Oligodendrocyte Glycoprotein... and other conditions

China
Novartis Pharmaceuticals

Active, not recruiting

PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma

Multiple Myeloma

Saudi Arabia, Germany, Singapore, Italy, France, Israel, United Kingdom, Japan, Australia, Spain, Brazil, United States, Greece, Canada
Memorial Sloan Kettering Cancer Center
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Active, not recruiting

BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma

Multiple Myeloma

United States
Pfizer

Active, not recruiting

A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment (MagnetisMM-9)

Multiple Myeloma

United States, Taiwan, Japan, United Kingdom
Novartis Pharmaceuticals

Active, not recruiting

BCMA-directed CAR-T Cell Therapy in Adult Patients With Multiple Myeloma

Multiple Myeloma

United States, Singapore, Israel, Australia
National Cancer Institute (NCI)

Active, not recruiting

T Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple Myeloma

Myeloma-Multiple | Myeloma, Plasma-Cell

United States
Juno Therapeutics, a Subsidiary of Celgene

Completed

Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma (EVOLVE)

Multiple Myeloma

United States
University of Washington
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

Clearance of 25-hydroxyvitamin D in Cystic Fibrosis (CF)

Cystic Fibrosis

United States
Cartesian Therapeutics

Active, not recruiting

Descartes-11 in Multiple Myeloma

Multiple Myeloma

United States
Amgen

Withdrawn

A Study of Subcutaneous (SC) AMG 701 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (ProxiMMity-1)

Relapsed/Refractory Multiple Myeloma
Cartesian Therapeutics

Completed

Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma

Multiple Myeloma

United States
National Cancer Institute (NCI)

Completed

T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma

Myeloma-Multiple | Myeloma, Plasma-Cell

United States
Cogent Biosciences, Inc.
Seagen Inc.

Terminated

Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma | Refractory Multiple Myeloma | Multiple Myeloma in Relapse

United States
Chinese PLA General Hospital

Unknown

Safety and Efficiency Study of BCMA-PD1-CART Cells in Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

China
Meiji Seika Pharma Co., Ltd.

Completed

A Study to Assess the Pharmacokinetic Profile, the Safety, and the Tolerability of ME1100 Inhalation Solution in Patients With Mechanically Ventilated Bacterial Pneumonia

Pneumonia, Bacterial

United States
The First Affiliated Hospital of Soochow University
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd; Suzhou Hongci Hematology...

Recruiting

Clinical Study of CAR-T Cell Therapy Following ASCT for R/R B-cell Non-Hodgkin's Lymphoma

Lymphoma, B-Cell | Autologous Stem Cell Transplantation

China
Instituto de Investigación Biomédica de Salamanca
Spanish Clinical Research Network - SCReN; Fundación Canaria de Investigación... and other collaborators

Recruiting

Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology (TranspoCART19)

B-cell Lymphoma Recurrent | Refractory B-Cell Lymphoma

Spain
National Cancer Institute (NCI)

Not yet recruiting

Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Chronic Lymphocytic Leukemia (CLL)

Leukemia, Lymphocytic, Chronic, B-Cell | B-Cell Chronic Lymphocytic Leukemia | B-Lymphocytic Leukemia, Chronic

United States
University Hospital, Montpellier

Not yet recruiting

Is Trogocytosis a Predictive Marker of CAR-T Cell Response in Diffuse Large B-cell Lymphoma? (CARTROG)

Diffuse Large B Cell Lymphoma
Baylor College of Medicine

Not yet recruiting

CHIMERIC ANTIGEN RECEPTOR TREATMENT TARGETING CD70 (SEVENTY) (CASEY)

Lymphoma | Leukemia, Myeloid, Acute | Leukemia, T-Cell | Leukemia, B-cell

United States
Stanford University
The Leukemia and Lymphoma Society

Recruiting

AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas

Follicular Lymphoma | Burkitt Lymphoma | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Lymphoplasmacytic Lymphoma | Hairy Cell Leukemia

United States
University of Utah

Recruiting

Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies (PRODIGY)

Acute Lymphoblastic Leukemia | Diffuse Large B Cell Lymphoma

United States
British Columbia Cancer Agency

Not yet recruiting

CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies

B-cell Lymphoma | Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | B-Cell Leukemia | B-cell Acute Lymphoblastic Leukemia | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | High-grade B-cell Lymphoma

Canada
Mayo Clinic

Recruiting

B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies

Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Chronic Lymphocytic Leukemia | Refractory Mantle Cell Lymphoma | Recurrent... and other conditions

United States
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Not yet recruiting

Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas

Hodgkin Lymphoma | Non-Hodgkin Lymphoma | Peripheral T-cell Lymphoma | Anaplastic Large Cell Lymphoma, ALK-Positive | Anaplastic Large Cell Lymphoma, ALK-negative | CD30-Positive Diffuse Large B-Cell Lymphoma | Anaplastic Large Cell Lymphoma, T Cell and Null Cell Type

United States
Shanghai Ming Ju Biotechnology Co., Ltd.

Recruiting

CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Large B-cell Lymphoma

Lymphoma, Non-Hodgkin | Diffuse Large B Cell Lymphoma

China
Shanghai Ming Ju Biotechnology Co., Ltd.

Not yet recruiting

Relmacabtagene Autoleucel in Hematologic Malignancies

Lymphoma, B-Cell | Follicular Lymphoma | Large B-cell Lymphoma

China
Shanghai Ming Ju Biotechnology Co., Ltd.

Recruiting

Relmacabtagene Autoleucel in Patients With LBCL

Large B-cell Lymphoma

China
H. Lee Moffitt Cancer Center and Research Institute
Kite, A Gilead Company

Recruiting

Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL

Large B-cell Lymphoma | Relapsed Non-Hodgkin Lymphoma

United States
Shanghai Ming Ju Biotechnology Co., Ltd.

Not yet recruiting

Relmacabtagene Autoleucel as Second-Line Therapy in Adult Patients With Aggressive B-cell NHL

Lymphoma, Large B-Cell, Diffuse | High-grade B-cell Lymphoma | Follicular Lymphoma Grade 3B | Mediastinal B-Cell Diffuse Large Cell Lymphoma

China
National Institute of Allergy and Infectious Diseases...
University of Pennsylvania Clinical Cell and Vaccine Production Facility...

Recruiting

CAR-T Cell Therapy for Desensitization in Kidney Transplantation

Kidney Failure | End Stage Renal Failure on Dialysis | Kidney Transplant

United States
Juventas Cell Therapy Ltd.

Not yet recruiting

A Study of HY004 Treatment in Adult Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r B-ALL) (B-ALL)

B-cell Acute Lymphoblastic Leukemia
Juventas Cell Therapy Ltd.

Not yet recruiting

Clinical Trial of HY004 Cell Injection in the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

Non-hodgkin Lymphoma
Medical College of Wisconsin

Not yet recruiting

LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies

Follicular Lymphoma | Burkitt Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Non Hodgkin Lymphoma | Diffuse Large B Cell Lymphoma
CARGO Therapeutics

Recruiting

A Phase 2 Study of CRG-022 in Patients With Relapsed/Refractory Large B-cell Lymphoma

Cancer | Relapsed/Refractory Large B-cell Lymphoma (LBCL)

United States
University Health Network, Toronto
Takara Bio Inc.

Recruiting

Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL

Relapsed or Refractory Chronic Lymphocytic Leukemia | Relapsed or Refractory Small Lymphocytic Lymphoma | Relapsed or Refractory CD19+ B-cell Lymphoma

Canada
Jennifer Crombie, MD
Merck Sharp & Dohme LLC

Recruiting

Pembro Plus CAR T-cell Therapy in R/R in PMBCL

Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Primary Mediastinal Large B Cell Lymphoma | T-Cell/Histiocyte-Rich Large B-Cell Lymphoma | Primary Mediastinal Large B-Cell Lymphoma Refractory | Primary Mediastinal Large B-Cell Lymphoma Recurrent | Epstein-Barr Virus Positive Diffuse Large...

United States
SWOG Cancer Research Network
National Cancer Institute (NCI); Incyte Corporation; Ipsen; BeiGene

Recruiting

Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | High Grade B-Cell Lymphoma | Grade 3b Follicular Lymphoma | Transformed Non-Hodgkin Lymphoma | High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements

United States
Joshua Sasine, MD, PhD

Recruiting

Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies

Multiple Myeloma | Acute Lymphoblastic Leukemia | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | Hematologic Malignancy | Large B-cell Lymphoma

United States
Dipenkumar Modi
Genmab

Recruiting

Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma

Relapsed Cancer | Refractory Cancer | Large Cell Lymphoma, Diffuse

United States
Technische Universität Dresden
German Cancer Research Center

Recruiting

A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies (CARLOTTA01)

Neoplasms | Multiple Myeloma in Relapse | Multiple Myeloma, Refractory | Relapsed Diffuse Large B-cell Lymphoma (DLBCL) | Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Germany

Search clinical trials for: B-cell Maturation Antigen

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Moldova

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations